ERBB2 and cancer: EpCAM and the number of clusters containing 2 or more cells (Clusters > 2) showed statistically significant differences (p = 0.022 and p = 0.007, respectively) in slope between HR+ and HER2+ cancers, indicating different biomarker rates of change over time between the two receptor subtypes.